Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML

Christoph Röllig • 26 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Midostaurin
MIDOKIT

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, discusses the results from the MIDOKIT trial (NCT01830361), which assessed the efficacy of midostaurin in patients with c-KIT or FLT3-ITD mutated t(8;21) acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Christoph Röllig

Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML 2:41
Venetoclax in combination with hypomethylating agents in adult patients with newly diagnosed CBF-AML
Christoph Röllig • 5 Dec 2025
Challenges associated with relapsed AML and the value of targeted agents 2:52
Challenges associated with relapsed AML and the value of targeted agents
Christoph Röllig • 3 Sep 2025
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML 2:18
Insights into the VINCENT trial: venetoclax + azacitidine versus intensive chemotherapy in NPM1m AML
Christoph Röllig • 3 Sep 2025
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML 2:19
Secondary-type mutations do not impact the favorable prognosis in NPM1-mutated AML
Christoph Röllig • 11 Dec 2023

Related Videos

Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib 3:37
Genomic assessment of acquired mutations in patients with CLL treated with nemtabrutinib
Thomas Kipps • 5 Dec 2025
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals